<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53597">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408445</url>
  </required_header>
  <id_info>
    <org_study_id>14-1720</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02408445</nct_id>
  </id_info>
  <brief_title>Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment</brief_title>
  <official_title>Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study in infant males with Klinefelter syndrome (47,XXY) will learn more about
      body composition (muscle and fat) and male hormones and look at the effect of testosterone
      shots on body composition. We know that older boys and men with Klinefelter syndrome often
      have more fat compared to muscle than adults without Klinefelter syndrome, but we do not
      know if this difference is present at birth or develops over time. We will learn if body
      composition and motor skills are improved with testosterone treatment in infants with
      Klinefelter syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body fat percentage</measure>
    <time_frame>3 months</time_frame>
    <description>Body fat percentage will be measured using air displacement plethysmography (PEA POD) at the beginning and end of the study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Luteinizing Hormone (LH)</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. Ultrasensitive LH will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Follicle Stimulating Hormone (FSH)</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. Ultrasensitive FSH will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Total Testosterone</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. Total testosterone by mass spectroscopy will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Inhibin B (INHB)</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. Inhibin B levels will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-Mullerian Hormone (AMH)</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. AMH levels will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>baseline only</time_frame>
    <description>Serum will be collected at the first study visit prior to randomization. Leptin levels will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on the Alberta Infant Motor Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Muscle tone and motor development will be assessed by an occupational therapist using the standardized Alberta Infant Motor Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on the Movement Assessment of Infants (MAI).</measure>
    <time_frame>3 months</time_frame>
    <description>Muscle tone and motor development will be assessed by an occupational therapist using the standardized Movement Assessment of Infants (MAI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on the Peabody Developmental Motor Scales 2</measure>
    <time_frame>3 months</time_frame>
    <description>Motor development will be assessed by an occupational therapist using the standardized Peabody Developmental Motor Scales 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penile length</measure>
    <time_frame>3 months</time_frame>
    <description>Stretched penile length will be measured by a physician before randomization and at the end of the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat free mass</measure>
    <time_frame>3 months</time_frame>
    <description>Fat free mass will be measured using air displacement plethysmography (PEA POD) at the beginning and end of the study period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Klinefelter Syndrome</condition>
  <arm_group>
    <arm_group_label>Testosterone treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone cypionate (200 mg/ml) intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will not receive any testosterone during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone cypionate 200mg/ml</intervention_name>
    <description>Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.</description>
    <arm_group_label>Testosterone treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male infants with 47,XXY karyotype

        Exclusion Criteria:

          -  Gestational age at birth &lt;36 weeks

          -  Birth weight &lt;5%ile or &gt;95% for gestational age

          -  History of thrombosis in a first degree relative

          -  Exposure to androgen therapy outside of the study protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>108 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanlee M Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shanlee M Davis, MD</last_name>
    <phone>720-777-6073</phone>
    <email>shanlee.davis@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Howell, MS, CGC, MBA</last_name>
    <phone>720-777-8361</phone>
    <email>susan.howell@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanlee M Davis, MD</last_name>
      <phone>720-777-6073</phone>
      <email>shanlee.davis@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Susan Howell, MS, CGC, MBA</last_name>
      <phone>720-777-8361</phone>
      <email>susan.howell@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Shanlee M Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip S Zeitler, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Tartalia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Regina Reynolds, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Howell, MS, CGC, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sydney Martin, OT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 27, 2016</lastchanged_date>
  <firstreceived_date>March 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>body composition</keyword>
  <keyword>Klinefelter syndrome</keyword>
  <keyword>XXY</keyword>
  <keyword>sex chromosome variation</keyword>
  <keyword>sex chromsome aneuploidy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Klinefelter Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
